Inogen (NASDAQ:INGN - Get Free Report)'s stock had its "hold" rating reissued by equities research analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports.
Separately, StockNews.com cut Inogen from a "buy" rating to a "hold" rating in a report on Friday, December 20th.
View Our Latest Research Report on Inogen
Inogen Stock Performance
Shares of INGN stock traded down $0.12 during trading hours on Thursday, hitting $11.57. The company had a trading volume of 157,389 shares, compared to its average volume of 251,297. Inogen has a 12 month low of $5.82 and a 12 month high of $13.33. The firm's fifty day moving average is $9.84 and its 200 day moving average is $10.14. The firm has a market capitalization of $275.60 million, a price-to-earnings ratio of -5.12 and a beta of 1.02.
Inogen (NASDAQ:INGN - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.26. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. The firm had revenue of $88.83 million for the quarter, compared to analysts' expectations of $83.68 million. During the same period in the prior year, the business posted ($1.97) earnings per share. On average, sell-side analysts expect that Inogen will post -1.73 EPS for the current fiscal year.
Institutional Trading of Inogen
Several hedge funds have recently modified their holdings of INGN. American Century Companies Inc. raised its position in shares of Inogen by 33.2% during the second quarter. American Century Companies Inc. now owns 38,627 shares of the medical technology company's stock worth $314,000 after acquiring an additional 9,626 shares during the last quarter. AQR Capital Management LLC lifted its position in Inogen by 29.3% during the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company's stock valued at $4,642,000 after purchasing an additional 129,307 shares during the period. Susquehanna Fundamental Investments LLC boosted its stake in shares of Inogen by 153.1% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 25,393 shares of the medical technology company's stock valued at $206,000 after purchasing an additional 15,361 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Inogen during the 2nd quarter worth approximately $457,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Inogen during the second quarter worth approximately $651,000. 89.94% of the stock is owned by institutional investors.
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
